Mobilization of Ph chromosome-negative peripheral blood stem cells in a child with chronic myeloid leukemia after imatinib-induced complete molecular remission

Pediatr Blood Cancer. 2008 Mar;50(3):639-41. doi: 10.1002/pbc.21017.

Abstract

Chronic myelogenous leukemia (CML) is rare in the pediatric population. Allogeneic stem cell transplant remains the only curative therapy; however, identifying a fully matched donor is not always possible. Imatinib mesylate has been shown to induce hematologic and cytogenetic response in adults and children with CML. We describe a child who achieved molecular remission with imatinib mesylate. BCR-ABL negative peripheral blood stem cells (PBSC) were successfully collected after mobilization with filgrastim.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Biomarkers, Tumor / blood
  • Bone Marrow Purging / methods*
  • Child
  • Filgrastim
  • Forecasting
  • Fusion Proteins, bcr-abl / blood
  • Granulocyte Colony-Stimulating Factor / pharmacology
  • Hematopoietic Stem Cell Mobilization*
  • Hematopoietic Stem Cells / enzymology
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myeloid, Chronic-Phase / blood*
  • Leukemia, Myeloid, Chronic-Phase / drug therapy
  • Male
  • Peripheral Blood Stem Cell Transplantation
  • Piperazines / therapeutic use*
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Recombinant Proteins
  • Remission Induction

Substances

  • Antineoplastic Agents
  • Benzamides
  • Biomarkers, Tumor
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl
  • Filgrastim